WELLBIOTEC CO.,LTD Logo

WELLBIOTEC CO.,LTD

Diversified in biopharma, EV chargers, and lithium supply for batteries.

010600 | KO

Overview

Corporate Details

ISIN(s):
KR7010600005
LEI:
Country:
South Korea
Address:
서울특별시 강남구 영동대로106길 17 5층, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

WELLBIOTEC CO., LTD. is a diversified company that has expanded from its foundational leather business into multiple high-growth sectors. The company's core activities now include a biopharmaceutical division that develops, produces, and sells pharmaceuticals, cosmeceuticals, and tissue regeneration products like PDRN through an extensive distribution network. It is also active in the energy and technology sectors, engaging in the rare earth minerals business with a focus on lithium ore for secondary batteries, and manufacturing electric vehicle (EV) chargers. Additional operations encompass a retail division for Home Meal Replacement (HMR) products, a global logistics and transportation agency, and a fashion business.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Audit Report / Information
반기검토의견부적정또는의견거절
Korean 6.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.3 MB
2025-06-05 00:00
Legal Proceedings Report
횡령ㆍ배임사실확인
Korean 6.6 KB
2025-05-27 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 32.3 KB
2025-05-27 00:00
Capital/Financing Update
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 32.3 KB
2025-05-20 00:00
Legal Proceedings Report
기타경영사항(자율공시) (상장폐지결정 효력정지 가처분 신청)
Korean 5.9 KB
2025-05-19 00:00
Delisting Announcement
기타시장안내 (상장·공시위원회 결과)
Korean 4.2 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-04-23 00:00
Delisting Announcement
기타시장안내 (개선계획 이행여부 심의요청서 접수)
Korean 10.4 KB
2025-04-14 00:00
Delisting Announcement
기타시장안내 (개선기간 종료)
Korean 8.0 KB
2025-04-10 00:00
Delisting Announcement
기타시장안내 (상장폐지 이의신청서 제출)
Korean 7.2 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.9 KB
2025-03-28 00:00
Annual Report
사업보고서 (2024.12)
Korean 2.4 MB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 21.3 KB
2025-03-21 00:00
Delisting Announcement
기타시장안내 (상장폐지 관련 안내)
Korean 9.2 KB

Automate Your Workflow. Get a real-time feed of all WELLBIOTEC CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for WELLBIOTEC CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for WELLBIOTEC CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

A pharmaceutical specialist in drugs for renal, skin, and allergic diseases.
Japan
4551
Tourmaline Bio, Inc. Logo
Develops an anti-IL-6 antibody for cardiovascular, inflammatory, and immune diseases.
United States of America
TRML
TOWA PHARMACEUTICAL CO.,LTD. Logo
Manufactures and markets high-quality, accessible generic drugs for various therapeutic areas.
Japan
4553
Transcode Therapeutics, Inc. Logo
Develops targeted RNA therapies for metastatic cancer using a proprietary nanoparticle delivery platform.
United States of America
RNAZ
Travere Therapeutics, Inc. Logo
Develops therapies for rare kidney and metabolic diseases, with an FDA-approved treatment for IgA nephropathy.
United States of America
TVTX
Traws Pharma, Inc. Logo
Develops oral small-molecule therapies for respiratory viral diseases and cancer.
United States of America
TRAW
TScan Therapeutics, Inc. Logo
Developing TCR-engineered T-cell therapies for solid and hematologic cancers.
United States of America
TCRX
TSUMURA & CO. Logo
A leader in Japanese Kampo herbal medicine, producing prescription and OTC formulations.
Japan
4540
TuHURA Biosciences, Inc./NV Logo
Phase 3 immuno-oncology firm developing therapeutics to overcome cancer therapy resistance.
United States of America
HURA
TURK İLAÇ VE SERUM SANAYİ A.Ş. Logo
Turkish producer of pharmaceuticals, specializing in IV solutions and vaccines for hospitals.
Türkiye
TRILC

Talk to a Data Expert

Have a question? We'll get back to you promptly.